Literature DB >> 29705589

Prevalence and correlates of neurological soft signs in healthy controls without family history of any mental disorder: A neurodevelopmental variation rather than a specific risk factor?

Konstantinos N Fountoulakis1, Panagiotis Panagiotidis2, Vasilios Kimiskidis3, Ioannis Nimatoudis2, Xenia Gonda4.   

Abstract

OBJECTIVE: Neurological soft signs (NSS) are a group of minor non-localizable neurological abnormalities found more often in patients with schizophrenia and other mental disorders. The aim of the current study was to investigate their prevalence and correlates in healthy controls without family history of any mental disorder.
MATERIAL AND METHODS: The study sample included 122 normal subjects (66 males and 56 females; aged 32.89 ± 9.91 years old). The assessment included the Neurological Evaluation Scale (NES), and a number of scales assessing the subthreshold symptoms (MADRS, STAI) and functioning (GAF). Data on a number of socio-demographic variables were also gathered. The statistical analysis included the development of basic statistics tables and the calculation of Pearson correlation coefficients.
RESULTS: The results of the current study suggest that more than half of the study sample manifested at least one NSS and approximately 5% more than four. Still, the reported prevalence and NES scores are lower form those reported in the literature probably because of the carefully selected study sample. There were no significant correlations between NSS and any socio-demographic or clinical variable. DISCUSSION: The current study is the first to study NSS in subjects without family history of any mental disorder and reports the presence of frequent silent neurodevelopmental events in the general population, probably in the form of a neurodevelopmental variation and possibly a weak generic rather than specific risk factor.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Motor coordination; Neurodevelopment; Neurological abnormalities; Risk factors; Soft neurological signs

Mesh:

Year:  2018        PMID: 29705589     DOI: 10.1016/j.ijdevneu.2018.04.006

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  7 in total

1.  Neurological soft signs and neurocognitive deficits in remitted patients with schizophrenia, their first-degree unaffected relatives, and healthy controls.

Authors:  Yingying Feng; Zongqin Wang; Guorong Lin; Hong Qian; Zuohui Gao; Xiaoli Wang; Mingcao Li; Xiaohua Hu; Yi Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-05-23       Impact factor: 5.270

2.  Paternal age and specific neurological soft signs as reliable and valid neurobiological markers for the diagnosis of patients with schizophrenia.

Authors:  Konstantinos N Fountoulakis; Panagiotis Panagiotidis; Thomas Tegos; Vasileios Kimiskidis; Ioannis Nimatoudis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-11-29       Impact factor: 5.760

3.  One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study.

Authors:  Konstantinos N Fountoulakis; Panagiotis Panagiotidis; Antonis T Theofilidis; Ioannis Nimatoudis
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-08-31       Impact factor: 2.582

4.  Postural Control in Childhood: Investigating the Neurodevelopmental Gradient Hypothesis.

Authors:  Leonardo Zoccante; Marco Luigi Ciceri; Liliya Chamitava; Gianfranco Di Gennaro; Lucia Cazzoletti; Maria Elisabetta Zanolin; Francesca Darra; Marco Colizzi
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

Review 5.  The neural substrates of neurological soft signs in schizophrenia: a systematic review.

Authors:  Genelle D Samson; Adrienne C Lahti; Nina V Kraguljac
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-26

6.  Neurological Soft Signs (NSS) in Census-Based, Decade-Adjusted Healthy Adults, 20 to >70 Years of Age.

Authors:  Silke Bachmann; Michaela Beck; Dai-Hua Tsai; Friederike Haupt
Journal:  Front Psychiatry       Date:  2021-06-24       Impact factor: 4.157

7.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.